Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543919 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT01543919: Completed Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Pfizer.
NCT01543919 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Pfizer. The registered enrollment target is 730 participants, below the 1,034-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01543919, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Obstructive Pulmonary Disease (COPD)
Conditions Studied
Interventions
- DRUG PH-797804
Study Locations (20)
Florida
- Pfizer Investigational Site - Brandon
- Pfizer Investigational Site - Chiefland
- Pfizer Investigational Site - Chiefland
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - New Port Richey
- Pfizer Investigational Site - Pensacola
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Williston
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Jasper
California
- Pfizer Investigational Site - Montclair
- Pfizer Investigational Site - San Diego
Arizona
- Pfizer Investigational Site - Phoenix
Connecticut
- Pfizer Investigational Site - Waterbury
Delaware
- Pfizer Investigational Site - Newark
Georgia
- Pfizer Investigational Site - Duluth
Kentucky
- Pfizer Investigational Site - Fort Mitchell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01543919 record still lists
NCT01543919 is an interventional study that assigns participants to a tested intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, below the 1,034-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which PH-797804 is the first listed.
NCT01543919 names 20 study sites across 8 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01543919 about?
NCT01543919 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide". PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Ob...
What is the current status of trial NCT01543919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2012-04. Estimated completion is 2013-09.
What conditions does trial NCT01543919 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT01543919?
The interventions under investigation include: PH-797804 (DRUG).
Who is sponsoring clinical trial NCT01543919?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01543919 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01543919's enrollment target sits among peer trials
730 22nd of 74 higher than 53 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia